Document:

Registration Rights Agreement dated July 19, 2006

 Exhibit 10.7 
 AUTOGENOMICS, INC. 
 REGISTRATION RIGHTS AGREEMENT 

This Registration Rights Agreement (this “Agreement”) is made as of this 19th day of July, 2006, by and among AutoGenomics, Inc., a California
corporation (the “Company”), MESA Development Inc. of Nevada, a Nevada corporation (“MESA Research”) and the purchasers of the Company’s Series C Convertible Preferred Stock (the “Series C
Preferred”) executing and delivering a counterpart signature page to this Agreement from time to time (together with Mesa Research, each individually, a “Purchaser” and collectively, the “Purchasers”).

 R E C I T A L S 
 A. Pursuant to that certain Series C Convertible Preferred Stock Purchase Agreement, of even date herewith (the “Purchase Agreement”), among the Company and the Purchasers, the Purchasers
are purchasing shares of the Series C Preferred and, as additional consideration for the purchase of the shares of the Series C Preferred, the Company is issuing to the Purchasers warrants (collectively, the “Warrants”) to purchase
additional shares of the Series C Preferred (the shares of Series C Preferred issuable upon exercise of the Warrants, the “Warrant Shares”). 
 B. It is a condition to the obligations of the Purchasers under the Purchase Agreement that this Agreement be executed by the parties hereto, and the parties are willing to execute this Agreement and to
be bound by the provisions hereof. 
 C. Capitalized terms not otherwise defined in this Agreement shall have the meanings
assigned to them in the Purchase Agreement. 
 A G R E E M E N T 

In consideration of the foregoing and the agreements set forth below, the parties agree with each other, as follows: 

1. DEFINITIONS. As used herein: 
 1.1 The term “Exchange Act” means the Securities Exchange Act of 1934, as amended. 
 1.2 The term “Holder” means any person owning or having the right to acquire Registrable Securities or any assignee thereof in accordance with Section 2.10 hereof.

 1.3 The terms “register,” “registered,” and “registration” refer to
a registration effected by preparing and filing a registration statement in compliance with the Securities Act (as defined below) and the applicable rules and regulations thereunder, and the declaration or ordering of the effectiveness of such
registration statement. 
 1.4 For the purposes hereof, the term “Registrable Securities” means and
includes (i) the shares of Common Stock of the Company issued or issuable upon conversion of the Series C Preferred, (ii) the shares of Common Stock of the Company issued or issuable upon conversion of the Warrant Shares, and
(iii) any Common Stock of the Company issued, or issuable upon the conversion 

 
or exercise of any warrant, right or other security which is issued, as a result of a stock split, dividend or other distribution with respect to or in exchange for or in replacement of the
shares referenced in (i) and (ii) above, excluding in all cases, however, any Registrable Securities (A) sold by a person in a transaction in which its rights under Section 2 are not assigned, (B) sold to or through a
broker or dealer or underwriter in a public distribution or a public securities transaction or otherwise sold in a transaction exempt from the registration and prospectus delivery requirements of the Securities Act under Section 4(1) thereof so
that all transfer restrictions, and restrictive legends with respect thereto, if any, are removed upon the consummation of such sale, or (C) held by a Holder who no longer is entitled to exercise any right provided in Section 2 in
accordance with Section 2.13 hereof. 
 1.5 The term “Ownership Percentage” means and
includes, with respect to each Holder of Registrable Securities requesting inclusion of Registrable Securities in an offering pursuant to this Agreement, the number of Registrable Securities held by such Holder divided by the aggregate number of all
Registrable Securities held by all Holders requesting registration in such offering. 
 1.6 The term “Public
Offering” means and includes the closing of an underwritten public offering pursuant to an effective registration statement under the Securities Act, covering the offer and sale of securities to the general public for the account of the
Company. 
 1.7 The term “Securities Act” means the Securities Act of 1933, as amended. 

2. REGISTRATION RIGHTS. 
 2.1 “Piggy Back” Registration. If at any time the Company shall determine to register under the Securities Act (including pursuant to a demand of any shareholder of the Company exercising
registration rights other than pursuant to Section 2.2 or Section 2.3 hereof) any of its Common Stock in connection with the public offering of such securities solely for cash (other than a registration relating solely to
(i) the sale of securities to participants in a Company employee benefits plan, (ii) equity securities issuable upon conversion of debt securities or (iii) a registration relating solely to a Rule 145 transaction), it shall send
to each Holder written notice of such determination and, if within ten (10) days after receipt of such notice, such Holder shall so request in writing, the Company shall use its best efforts to include in such registration statement all or any
part of the Registrable Securities that such Holder requests to be registered, except that if, in connection with any offering involving an underwriting of Common Stock to be issued by the Company, the managing underwriter shall impose a limitation
on the number of shares of Common Stock included in any such registration statement because, in such underwriter’s judgment, such limitation is necessary based on market conditions, (a) if such offering is the initial Public Offering of
the Company’s securities solely for the Company’s own account, the Holders may be excluded entirely if the underwriters make the determination described above, and (b) if such offering is not the initial Public Offering of the
Company’s securities or if the underwriters otherwise do not entirely exclude the Registrable Securities from the registration, the Company shall be obligated to include in such registration statement, with respect to the requesting Holder,
only an amount of Registrable Securities equal to the product of (i) the number of Registrable Securities that remain available for registration after the underwriter’s cut back and (ii) such Holder’s Ownership Percentage;
provided, however, in either case, no Registrable Securities shall be reduced or excluded from any registration unless all other securities other than the Registrable Securities are first entirely excluded from such registration.

  
 2 

 If any Holder disapproves of the terms of such underwriting, he may elect to withdraw
therefrom by written notice to the Company and the underwriter. No incidental right under this Section 2.1 shall be construed to limit any registration required under Section 2.2. 

2.2 Required Registration. 
 (a) On two (2) occasions after the date that is the earlier of (i) Monday, July 19, 2010, and (ii) one hundred eighty (180) days after the consummation of the initial Public
Offering, Holders of at least a majority of the Registrable Securities then outstanding may require the Company to register such Holders’ Registrable Securities under the Securities Act. Such Holders shall notify the Company in writing that it
or they intend to offer or cause to be offered for public sale of all or any portion of the Registrable Securities, and within ten (10) days of the receipt after such notice, the Company will so notify all Holders of Registrable Securities.

 (b) Upon written request of any Holder given within thirty (30) days after the receipt by such Holder from the Company
of such notification, the Company will use its best efforts to cause all or any part of the Registrable Securities that may be requested by any Holder thereof (including the Holders giving the initial notice of intent to offer (each an
“Initiating Holder” and collectively the “Initiating Holders”)) to be registered under the Securities Act as expeditiously as possible; provided, however, that the Company shall not be obligated to
effect any such registration pursuant to this Section 2.2 unless the proposed aggregate dollar amount of the offering (valued at the high end of a proposed offering range) of the Registrable Securities requested to be included is at
least $10,000,000. 
 (c) Notwithstanding anything contained in this Section 2.2 or Section 2.3 to the
contrary, if the Company furnishes to the Holders requesting any registration pursuant to such sections a certificate signed by the President of the Company stating that, in the good faith judgment of the Board of Directors of the Company, such
registration would be detrimental to the Company and that it is in the best interests of the Company to defer the filing of a registration statement, then the Company shall have the right to defer the filing of a registration statement with respect
to such offering for a period of not more than one hundred and eighty (180) days from receipt by the Company of the request by the Initiating Holder; provided, however, that the Company may not exercise such right more than once
in any twelve-month period. 
 (d) If the Initiating Holders intend to distribute the Registrable Securities covered by their
request by means of an underwriting, they shall so advise the Company as part of their request and the Company shall include such information in the written notice referred to above. 

(e) The underwriter shall be selected by a majority in interest of the Initiating Holders and shall be reasonably acceptable to the
Company. In such event, the right of any Holder to include his, her or its Registrable Securities in such registration shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s
Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall enter into an underwriting agreement in customary form with the underwriters selected for
such underwriting. 
 (f) Notwithstanding the foregoing, if the managing underwriter shall impose a limitation on the number of
shares of Common Stock included in any such registration statement because, in such underwriter’s judgment, such limitation is necessary based on market 

  
 3 

 
conditions, the Company shall be obligated to include in such registration statement, with respect to the Holders of Registrable Securities which would otherwise be underwritten pursuant hereto,
only an amount of Registrable Securities equal to the product of (i) the number of Registrable Securities that remain available for registration after the underwriter’s cut back and (ii) such Holder’s Ownership Percentage;
provided, however, that the number of Registrable Securities to be included in such underwriting shall not be reduced unless all other securities other than the Registrable Securities are first entirely excluded from the underwriting.

 (g) Notwithstanding the foregoing, the Company shall not be obligated to effect, or to take any action to effect, any
registration pursuant to this Section 2.2: (i) after the Company has effected two (2) registrations pursuant to this Section 2.2 and such registrations have been declared or ordered effective; (ii) during the
period ending on a date one hundred eighty (180) days after the consummation of the initial Public Offering; or (iii) if within thirty (30) days after receipt by the Company of the Holders’ initial notice of intent to offer, the
Company furnishes to such Holders requesting registration a certificate signed by the President of the Company stating the Company’s intent to file a registration statement for the initial Public Offering within the following ninety
(90) days. 
 2.3 Registration on Form S-3. At any time after the Company becomes eligible to register Registrable
Securities for resale on Form S-3, or any similar form subsequently adopted by the Securities and Exchange Commission (“SEC”) which permits incorporation of substantial information by reference to other documents filed by the
Company with the SEC (“Form S-3”), if the Company shall receive from one or more Holder or Holders of the Registrable Securities a written request or requests that the Company effect a registration on Form S-3 and any related
qualification or compliance with respect to all or a part of the Registrable Securities owned by such Holder or Holders, the Company will: 
 (a) promptly give written notice of the proposed registration, and any related qualification or compliance, to all other Holders; and 

(b) as soon as practicable, effect such registration and all such qualifications and compliances as may be so requested and as would
permit or facilitate the sale and distribution of all or such portion of such Holder’s or Holders’ Registrable Securities as are specified in such request, together with all or such portion of the Registrable Securities of any other Holder
or Holders joining in such request as are specified in a written request given within fifteen (15) days after receipt of such written notice from the Company; provided, however, that the Company shall not be obligated to effect
any such registration, qualification or compliance, pursuant to this Section 2.3: (1) if Form S-3 is not available for such offering by the Holders; (2) if the Company furnishes to the Holders requesting any registration
pursuant to this Section 2.3 a certificate signed by the President of the Company stating that, in the good faith judgment of the Board of Directors of the Company, such Form S-3 registration would be detrimental to the Company and that
it is in the best interests of the Company to defer the filing of such registration statement, then the Company shall have the right to defer the filing of the Form S-3 registration statement with respect to such offering for a period of not more
than ninety (90) days from receipt by the Company of the request by the Initiating Holder; provided, however, that the Company may not exercise such right more than once in any twelve-month period; (3) if such Form S-3
registration statement covers an offering of less than $500,000 of Registrable Securities; (4) if the Holders are otherwise eligible to sell their Registrable Securities under Rule 144 of the Securities Act; or (5) during the period
ending on a date one hundred eighty (180) days after the effective date of a registration pursuant to Section 2.2 hereof or this Section 2.3. 

  
 4 

 (c) Subject to the foregoing, the Company shall file a registration statement covering the
Registrable Securities and other securities so requested to be registered as soon as practicable after receipt of the request or requests of the Holders. Registrations effected pursuant to this Section 2.3 shall not be counted as demands
for registration effected pursuant to Section 2.2. 
 2.4 Effectiveness. 

(a) The Company will use its best efforts to maintain the effectiveness for at least ninety (90) days of any registration statement
pursuant to which any of the Registrable Securities are being offered or until the distribution described in such registration statement is completed, if earlier; provided, however, that: (i) such period shall be extended for a
period of time equal to the period the Holder refrains from selling any securities included in such registration at the request of an underwriter of Common Stock (or other securities) of the Company and (ii) in the case of any registration of
Registrable Securities on Form S-3 which are intended to be offered on a continuous or delayed basis, such period shall be extended, if necessary, to keep the registration statement effective until the earlier to occur of (A) one hundred and
eighty (180) days following the effectiveness of the registration statement, or (B) the date that all such Registrable Securities are sold, provided that Rule 415, or any successor rule under the Securities Act, permits an offering on
a continuous or delayed basis, and provided further that applicable rules under the Securities Act governing the obligation to file a post-effective amendment permit, in lieu of filing a post-effective amendment which (I) includes any
prospectus required by Section 10(a)(3) of the Securities Act or (II) reflects facts or events representing a material or fundamental change in the information set forth in the registration statement, the incorporation by reference of
information required to be included in (I) and (II) above to be contained in periodic reports filed pursuant to Section 13 or 15(d) of the Exchange Act in the registration statement. 

(b) The Company will from time to time amend or supplement such registration statement and the prospectus contained therein as and to
the extent necessary to comply with the Securities Act and any applicable state securities statute or regulation. 
 2.5
Indemnification. 
 (a) Indemnification of Holders. In the event that the Company registers any of the Registrable
Securities under the Securities Act, the Company will, to the extent permitted by law, indemnify and hold harmless each Holder, its legal counsel and independent accountants, and each of their officers, directors and partners, and each underwriter
of the Registrable Securities so registered (including any broker or dealer through whom such shares may be sold) and each person, if any, who controls such Holder or any such underwriter within the meaning of Section 15 of the Securities Act
from and against any and all losses, claims, damages, expenses or liabilities (or any action in respect thereof), joint or several, to which they or any of them become subject under the Securities Act or under any other statute or at common law or
otherwise, and, except as hereinafter provided, will reimburse each such Holder, each such underwriter and each such controlling person, if any, for any legal or other expenses reasonably incurred by them or any of them, as such expenses are
incurred, in connection with investigating or defending any actions whether or not resulting in any liability, insofar as such losses, claims, damages, expenses, liabilities or actions arise out of or

  
 5 

 
are based upon (i) any untrue statement or alleged untrue statement of a material fact contained in the registration statement, in any preliminary or amended preliminary prospectus or in the
prospectus (or the registration statement or prospectus as from time to time amended or supplemented by the Company); (ii) arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated
therein or necessary in order to make the statements therein not misleading; or (iii) any violation by the Company of the Securities Act, the Exchange Act, a state securities law or any rule or regulation under the Securities Act, the Exchange
Act or any state securities law; provided, however, that the indemnity contained in this Section 2.5(a) will not apply where such untrue statement or omission was made in such registration statement, preliminary or amended,
preliminary prospectus or prospectus in reliance upon and in conformity with information furnished in writing to the Company in connection therewith by such Holder of Registrable Securities, any such underwriter or any such controlling person
expressly for use therein. Promptly after receipt by any Holder of Registrable Securities, any underwriter or any controlling person of notice of the commencement of any action in respect of which indemnity may be sought against the Company, such
Holder of Registrable Securities, or such underwriter or such controlling person, as the case may be, will notify the Company in writing of the commencement thereof, and, subject to the provisions hereinafter stated, the Company shall assume the
defense of such action (including the employment of counsel, who shall be counsel reasonably satisfactory to such Holder of Registrable Securities, such underwriter or such controlling person, as the case may be), and the payment of expenses insofar
as such action shall relate to any alleged liability in respect of which indemnity may be sought against the Company. Such Holder of Registrable Securities, any such underwriter or any such controlling person shall have the right to employ separate
counsel in any such action and to participate in the defense thereof in the event the representation of such Holder, underwriter or controlling person by counsel retained by or on the behalf of the Company would be inappropriate due to conflicts of
interest between any such person and any other party represented by such counsel in such proceeding or action, in which case the Company shall pay, as incurred, the fees and expenses of one (1) such separate counsel. The Company shall not be
liable to indemnify any person under this Section 2.5(a) for any settlement of any such action effected without the Company’s consent (which consent shall not be unreasonably withheld). The Company shall not, except with the
approval of each party being indemnified under this Section 2.5(a) (which approval will not be unreasonably withheld), consent to entry of any judgment or enter into any settlement that does not include as an unconditional term thereof
the giving by the claimant or plaintiff to the parties being so indemnified of a release from all liability in respect to such claim or litigation. 
 (b) Indemnification of Company. In the event that the Company registers any of the Registrable Securities under the Securities Act, each Holder of the Registrable Securities so registered will, to
the extent permitted by law, indemnify and hold harmless the Company, each of its directors, each of its officers who have signed the registration statement, each underwriter of the Registrable Securities so registered (including any broker or
dealer through whom any of such shares may be sold), and each person, if any, who controls the Company, within the meaning of Section 15 of the Securities Act from and against any and all losses, claims, damages, expenses or liabilities (or any
action in respect thereof), joint or several, to which they or any of them may become subject under the Securities Act or under any other statute or at common law or otherwise, and, except as hereinafter provided, will reimburse the Company and each
such director, officer, underwriter or controlling person for any legal or other expenses reasonably incurred by them or any of them, as such expenses are incurred, in connection with investigating or defending any actions whether or not resulting
in any liability, insofar as such losses, claims, damages, expenses, liabilities or actions arise out of or are based upon any untrue statement or alleged untrue statement of a material fact contained in the registration statement, in any
preliminary or amended preliminary prospectus or in the 

  
 6 

 
prospectus (or the registration statement or prospectus as from time to time amended or supplemented) or arise out of or are based upon the omission or alleged omission to state therein a
material fact required to be stated therein or necessary in order to make the statements therein not misleading, but only insofar as any such statement or omission was made in reliance upon and in conformity with information furnished in writing to
the Company in connection therewith by such Holder, expressly for use therein; provided, however, that such Holder’s obligations hereunder shall be limited to an amount equal to the proceeds to such Holder of the Registrable
Securities sold in such registration, except in the case of fraud by such Holder. Promptly after receipt of notice of the commencement of any action in respect of which indemnity may be sought against such Holder of Registrable Securities, the
Company will notify such Holder of Registrable Securities in writing of the commencement thereof, and such Holder of Registrable Securities shall, subject to the provisions hereinafter stated, assume the defense of such action (including the
employment of counsel, who shall be counsel satisfactory to the Company) and the payment of expenses insofar as such action shall relate to the alleged liability in respect of which indemnity may be sought against such Holder of Registrable
Securities. The Company and each such director, officer, underwriter or controlling person shall have the right to employ separate counsel in any such action and to participate in the defense thereof in the event the representation of the Company,
any of its officers or directors or any underwriter or controlling person by counsel retained by or on the behalf of such Holder would be inappropriate due to conflicts of interest between any such person and any other party represented by such
counsel in such proceeding or action, in which case such Holder shall pay, as incurred, the fees and expenses of one (1) such separate counsel. Notwithstanding the two preceding sentences, if the action is one in which the Company may be
obligated to indemnify any Holder of Registrable Securities pursuant to Section 2.5(a), the Company shall have the right to assume the defense of such action, subject to the right of such holders to participate therein as permitted by
Section 2.5(a). Such Holder shall not be liable to indemnify any person for any settlement of any such action effected without such Holder’s consent (which consent shall not be unreasonably withheld). Such Holder shall not, except
with the approval of the Company (which approval shall not be unreasonably withheld), consent to entry of any judgment or enter into any settlement that does not include as an unconditional term thereof the giving by the claimant or plaintiff to the
party being so indemnified of a release from all liability in respect to such claim or litigation. 
 (c) The obligations of
the Company and the Holders under this Section 2.5 shall survive the completion of any offering of Registrable Securities in a registration statement under this Agreement, and otherwise. 

2.6 Contribution. If the indemnification provided for in Section 2.5 is held by a court of competent jurisdiction to
be unavailable to an indemnified party with respect to any loss, liability, claim, damage, or expense referred to therein, then the indemnifying party, in lieu of indemnifying such indemnified party hereunder, shall contribute to the amount paid or
payable by such indemnified party as a result of such loss, liability, claim, damage, or expense in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one hand and of the indemnified party on the other
in connection with the statements or omissions that resulted in such loss, liability, claim, damage, or expense as well as any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall
be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material fact relates to information supplied by the indemnifying party or by the indemnified party and
the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission. Notwithstanding the provisions of Section 2.5 hereof or this Section 2.6, to the extent
that the provisions on indemnification and 

  
 7 

 
contribution contained in the underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the
underwriting agreement shall control. 
 2.7 Exchange Act Registration. With a view to making available to the Holders
the benefits of Rule 144 promulgated under the Securities Act and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on
Form S-3, the Company agrees to: 
 (a) use its best efforts to make and keep public information available, as those terms are
understood and defined in SEC Rule 144, at all times after ninety (90) days after the effective date of the first registration statement filed by the Company for the offering of its securities to the general public; 

(b) take such reasonable action, including the voluntary registration of its Common Stock under Section 12 of the Exchange Act, as
is necessary to enable the Holders to utilize Form S-3 for the sale of their Registrable Securities, such action to be taken as soon as practicable after the end of the fiscal year in which the first registration statement filed by the Company for
the offering of its securities to the general public is declared effective; 
 (c) file on a timely basis with the SEC all
information that the SEC may require under either of Section 13 or Section 15(d) of the Exchange Act and, so long as it is required to file such information, take all action that may be required as a condition to the availability of
Rule 144 under the Securities Act (or any successor exemptive rule hereinafter in effect) with respect to the Company’s Common Stock; and 
 (d) furnish to any Holder forthwith upon request (i) a written statement by the Company as to its compliance with the reporting requirements of Rule 144, (ii) a copy of the most recent
annual or quarterly report of the Company as filed with the SEC, and (iii) any other reports and documents that a Holder may reasonably request in availing itself of any rule or regulation of the SEC allowing a Holder to sell any such
Registrable Securities without registration. 
 2.8 Further Obligations of the Company. Whenever the Company is required
hereunder to register Registrable Securities, it agrees that it shall also do the following: 
 (a) furnish to each selling
Holder such copies of each preliminary and final prospectus and any other documents that such Holder may reasonably request to facilitate the public offering of its Registrable Securities; 

(b) use its best efforts to register or qualify the Registrable Securities to be registered pursuant to this Agreement under the
applicable securities or “blue sky” laws of such jurisdictions as any selling Holder may reasonably request; provided, however, that the Company shall not be obligated to qualify to do business in any jurisdiction where it is
not then so qualified or to take any action that would subject it to the service of process in suits other than those arising out of the offer or sale of the securities covered by the registration statement in any jurisdiction where it is not then
so subject; 
 (c) notify each Holder of Registrable Securities covered by such registration statement at any time when a
prospectus relating thereto is required to be delivered under 

  
 8 

 
the Securities Act of the happening of any event as a result of which the prospectus included in such registration statement, as then in effect, includes an untrue statement of a material fact or
omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing; 
 (d) cause all such Registrable Securities registered pursuant hereunder to be listed on each securities exchange on which similar securities issued by the Company are then listed; 

(e) provide a transfer agent and registrar for all Registrable Securities registered pursuant hereunder and a CUSIP number for all such
Registrable Securities, in each case not later than the effective date of such registration; 
 (f) in the event of any
underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and customary form, with the managing underwriter of such offering. Each Holder participating in such underwriting shall also enter into
and perform its obligations under such an agreement; 
 (g) furnish, at the request of any Holder requesting registration of
Registrable Securities pursuant to this Section 2, on the date that such Registrable Securities are delivered to the underwriters for sale in connection with a registration pursuant to this Section 2, if such securities are
being sold through underwriters, or, if such securities are not being sold through underwriters, on the date that the registration statement with respect to such securities becomes effective: 

(i) an opinion, dated such date, of the counsel representing the Company for the purposes of such registration, in form and substance as
is customarily given to underwriters in an underwritten public offering, addressed to the underwriters, if any, and to the Holders requesting registration of Registrable Securities; and 

(ii) “comfort” letters signed by the Company’s independent public accountants who have examined and reported on the
Company’s financial statements included in the registration statement, to the extent permitted by the standards of the American Institute of Certified Public Accountants, covering substantially the same matters with respect to the registration
statement (and the prospectus included therein) and (in the case of the accountants’ “comfort” letters) with respect to events subsequent to the date of the financial statements, as are customarily covered in opinions of issuer’s
counsel and in accountants’ “comfort” letters delivered to the underwriters in underwritten public offerings of securities, but only if and to the extent that the Company is required to deliver or cause the delivery of such opinion or
“comfort” letters to the underwriters in an underwritten public offering of securities; 
 (h) permit each selling
Holder or his, her or its counsel or other representatives to inspect and copy such corporate documents and records as may reasonably be requested by them for a bona fide purpose in connection with this Agreement; and 

(i) furnish to each selling Holder, upon request, a copy of all documents filed and all correspondence from or to the SEC in connection
with any such offering unless confidential treatment of such information has been requested of the SEC. 

  
 9 

 2.9 Expenses. In the case of a registration under Sections 2.1, 2.2 or
2.3 the Company shall bear all costs and expenses of each such registration, including, but not limited to, printing, legal and accounting expenses, SEC filing fees and “blue sky” fees and expenses; provided, however,
that the Company shall have no obligation to pay or otherwise bear any portion of the underwriter’s commissions or discounts attributable to the Registrable Securities being offered and sold by the Holders of Registrable Securities. 

2.10 Transfer of Registration Rights. The registration rights of a Holder of Registrable Securities under this Agreement may be
transferred (but only with all related obligations) to a transferee or assignee which receives at least twenty percent (20%) of the Registrable Securities then held by the Holder, provided that, such transfer or assignment shall be effective
only if the transferee agrees to be bound by this Agreement, such transfer or assignment satisfies the transfer requirements set forth in the Investors’ Rights Agreement (as defined in Section 2.3 of the Purchase Agreement) and complies
with federal and state securities laws, and that the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee or assignee and the securities with respect to which such
registration rights are being transferred. 
 2.11 No Superior Rights. The Company will not grant registration rights to
any person or entity that are superior to the rights granted hereunder without first obtaining the prior written consent of the Holders of at least a majority of then outstanding Registrable Securities; provided, however, that this restriction shall
not apply to a grant of registration rights to investors in connection with a private offering of the Company’s securities in which the Company receives gross proceeds of at least $20 million. 

2.12 Market Stand-Off Agreement. Provided that all Holders are treated equally and all officers and directors of the Company are
also so bound, no Holder shall, to the extent requested by any managing underwriter of the Company, sell or otherwise transfer or dispose of (other than to donees who agree to be similarly bound) any Registrable Securities during a period (the
“Stand-Off Period”) not to exceed 180 days following the effective date of a registration statement under the Securities Act, (or in each case such shorter period as the Company or managing underwriter may authorize), and except in
each case, for securities sold as part of the offering covered by such registration statement in accordance with the provisions of this Agreement, and further agrees to execute an agreement reflecting the foregoing as may be requested by the
underwriters at the time of such Public Offering. In order to enforce the foregoing covenant, the Company may impose stock transfer restrictions with respect to the Registrable Securities of each Holder until the end of the Stand-Off Period. Each
Holder agrees that it will not transfer securities of the Company unless such transferee agrees in writing to be bound by the provisions of this Section 2.12. 
 Notwithstanding the foregoing, the obligations described in this Section 2.12 shall not apply to a registration relating solely to employee benefit plans on Form S-1 or Form S-8 or similar
forms which may be promulgated in the future, or a registration relating solely to an SEC Rule 145 transaction on Form S-4 or similar forms which may be promulgated in the future. 

2.13 Termination of Registration Rights. The obligations of the Company to register any Holder’s Registrable Securities
pursuant to this Section 2 shall terminate if all of a Holder’s Registrable Securities may be sold under Rule 144 during any ninety (90) day period. 

  
 10 

 3. MISCELLANEOUS. 

3.1 Governing Law. This Agreement shall be governed by and construed under the laws of the State of California as applied to
agreements among California residents, made and to be performed entirely within the State of California. 
 3.2 Successors
and Assigns. Except as otherwise expressly provided herein, the provisions hereof shall inure to the benefit of, and be binding upon, the successors, assigns, heirs, executors, and administrators of the parties hereto. 

3.3 Entire Agreement. This Agreement, the Purchase Agreement and the exhibits and other documents delivered pursuant to the
Purchase Agreement, constitute the full and entire understanding and agreement among the parties with regard to the subjects hereof and no party shall be liable or bound to any other party in any manner by any representations, warranties, covenants,
or agreements except as specifically set forth herein or therein. Nothing in this Agreement, express or implied, is intended to confer upon any party, other than the parties hereto and their respective successors and assigns, any rights, remedies,
obligations, or liabilities under or by reason of this Agreement, except as expressly provided herein. 
 3.4
Severability. Any invalidity, illegality, or limitation of the enforceability of any one or more of the provisions of this Agreement, or any part thereof, shall in no way affect or impair the validity, legality, or enforceability of this
Agreement with respect to any other term or provision. In case any provision of this Agreement shall be invalid, illegal, or unenforceable, it shall, to the extent practicable, be modified so as to make it valid, legal and enforceable and to retain
as nearly as practicable the intent of the parties, and the validity, legality, and enforceability of the remaining provisions shall not in any way be affected or impaired thereby. 

3.5 Amendment and Waiver. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived
with the written consent of the Company and the Holders of not less than a majority of then outstanding Registrable Securities; provided, however, that no such amendment or waiver shall reduce the aforesaid percentage requirement
without the consent of the Holders of all of such Registrable Securities. Any amendment or waiver effected in accordance with this paragraph shall be binding upon all of the parties hereto and their then existing and future successors and assigns.
Upon the effectuation of each such amendment or waiver, the Company shall promptly give written notice thereof to the record holders of any Registrable Securities of the Company who have not previously consented thereto in writing. 

3.6 Delays or Omissions. No delay or omission to exercise any right, power, or remedy accruing to the Holders of Registrable
Securities upon any breach, default or noncompliance of the Company under this Agreement shall impair any such right, power, or remedy, nor shall it be construed to be a waiver of any such breach, default or noncompliance, or any acquiescence
therein, or of any similar breach, default or noncompliance thereafter occurring. It is further agreed that any waiver, permit, consent, or approval of any kind or character on the Holders’ part of any breach, default or noncompliance under
this Agreement, or any waiver on the Holders’ part of any provisions or conditions of this Agreement, must be in writing and shall be effective only to the extent specifically set forth in such writing, and that all remedies under this
Agreement, under law, or otherwise afforded to the Holders, shall be cumulative and not alternative. 

  
 11 

 3.7 Notices, etc. All notices and other communications required or permitted
hereunder shall be in writing and shall be deemed effectively given upon personal delivery, upon confirmed facsimile transmission, on the next business day following mailing by professional overnight courier service or on the third day following
mailing by registered or certified mail, return receipt requested, postage prepaid, addressed as follows: 
  

	 	(a)	if to a Purchaser, at such Purchaser’s address as set forth on such Purchaser’s counterpart signature page hereto; 

 

	 	(b)	if to the Company, at 

AutoGenomics, Inc. 
 2251 Rutherford Road 
 Carlsbad, CA 92008 

Attention: Fareed Kureshy, President & CEO 
 Facsimile: (760) 804-7382 
 with a copy to 

Bingham McCutchen LLP 
 600 Anton Boulevard, 18th Floor 
 Costa Mesa, CA 92626 

Attention: James W. Loss, Esq. 
 Facsimile: (714) 830-0726 
 (c) Any party may at any time change the address
to which notice to such party shall be mailed by giving notice of such change to all of the other parties pursuant to this Section 3.7. 
 3.8 Attorneys’ Fees. If any action at law or in equity is necessary to enforce or interpret the terms of this Agreement, the prevailing party shall be entitled to reasonable attorneys’
fees, costs and necessary disbursements in addition to any other relief to which such party may be entitled as determined by such court or proceeding. 
 3.9 Titles and Subtitles. The titles of the paragraphs and subparagraphs of this Agreement are for convenience of reference only and are not to be considered in construing this Agreement.

 3.10 Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed an
original, but all of which together shall constitute one instrument. 
 [remainder of this page intentionally left blank]

  
 12 

 COUNTERPART PURCHASER SIGNATURE PAGE TO 

AUTOGENOMICS, INC.  
 REGISTRATION RIGHTS AGREEMENT 
 The undersigned, in its capacity as
a Purchaser, hereby executes and delivers the Registration Rights Agreement to which this signature page is attached and agrees to be bound by the Registration Rights Agreement on the date set forth on the first page of the Registration Rights
Agreement. This counterpart signature page, together with all counterparts of the Registration Rights Agreement and signature pages of the other parties named therein, shall constitute one and the same instrument in accordance with the terms of the
Registration rights Agreement. 
 “THE COMPANY” 
 AUTOGENOMICS, INC., 
 a California corporation 

 

			
		
	By:	 	 /s/ Fareed Kureshy

		 	Fareed Kureshy, President & CEO

 “PURCHASERS” 
 “Mesa Research” 
 MESA Development Inc. of Nevada, 

a Nevada corporation 
  

			
		
	By:	 	 /s/ William H. Davidson

		 	William H. Davidson, President & Treasurer

  

	
	
	 Selah Trust

	 [Print Name of Purchaser]

	
	 /s/ William T. Baker

	 [Signature]

			
	Name:	 	 William T. Baker

			
	Title:	 	 Trustee

							
		
	 Joseph P. Sullivan
	 	
	[Print Name of Purchaser]	 	
		
	 /s/ Joseph P. Sullivan
	 	
	[Signature]	 	
	Name:	 	 Joseph P. Sullivan
	 	 	 	

							
	Title:	 	  
	 	 	 	

							
		
	 Dennis D. Curtin
	 	 Karen E. Hogan Curtin

	[Print Name of Purchaser]	 	[Name of Co-Purchaser, if applicable]
		
	 /s/ Dennis D. Curtin
	 	 /s/ Karen E. Hogan Curtin

	[Signature]	 	[Signature]
	Name:	 	 Dennis D. Curtin
	 	Name:	 	 Karen E. Hogan Curtin

							
	Title:	 	  
	 	Title:	 	  

							
			
	 Bamboo LLC
	 		 	
	[Print Name of Purchaser]	 		 	
		
	 /s/ Nolan T. Higa
	 	
	[Signature]	 	
	Name:	 	 Nolan T. Higa
	 	 	 	

							
	Title:	 	 Manager
	 	 	 	

							
		
	 Roger I. MacFarlane
	 	
	[Print Name of Purchaser]	 	
		
	 /s/ Roger I. MacFarlane
	 	
	[Signature]	 	
	Name:	 	 Roger I. MacFarlane
	 	 	 	

							
	Title:	 	  
	 	 	 	

	
	
	 Warren H. Lortie Trust

	[Print Name of Purchaser]
	
	 /s/ Warren H. Lortie

	[Signature]

			
	Name:	 	 Warren H. Lortie

			
	Title:	 	 Trustee

	
	
	 Rue Family Trust Utd. 2/10/89

	[Print Name of Purchaser]
	
	 /s/ Michael M. Rue

	[Signature]

			
	Name:	 	 Michael M. Rue

			
	Title:	 	 Trustee

	
	
	 Tregale Group Limited

	[Print Name of Purchaser]
	
	 /s/ Tregale Group Limited

	[Signature]

			
	Name:	 	 Tregale Group Limited

			
	Title:	 	  

	
	
	 AR Properties

	[Print Name of Purchaser]
	
	 /s/ Randall J. Repp

	[Signature]

			
	Name:	 	 Randall J. Repp

			
	Title:	 	 General Partner

							
		
	 Harold F. McGrath
	 	 Hilary McGrath

	[Print Name of Purchaser]	 	[Name of Co-Purchaser, if applicable]
		
	 /s/ Harold F. McGrath
	 	 /s/ Hilary McGrath

	[Signature]	 	[Signature]
	Name:	 	 Harold F. McGrath
	 	Name:	 	 Hilary McGrath

							
	Title:	 	 Joint Tenant
	 	Title:	 	 Joint Tenant

							
			
	 Linda Formo Brandes
	 		  	
	[Print Name of Purchaser]	 		  	
			
	 /s/ Linda Formo Brandes
	 		  	
	[Signature]	 		  	
	Name:	 	 Linda Formo Brandes
	 		  	

							
	Title:	 	  
	 		  	

							
			
	 Josh Tolkoff
	 		  	
	[Print Name of Purchaser]	 		  	
			
	 /s/ M.J. Tolkoss
	 		  	
	[Signature]	 		  	
	Name:	 	 M.J. Tolkoss
	 		  	

							
	Title:	 	  
	 		  	

							
		
	 Bradley A. Danielson
	 	 Jone L. Danielson

	[Print Name of Purchaser]	 	[Name of Co-Purchaser, if applicable]
		
	 /s/ Bradley A. Danielson
	 	 /s/ Jone L. Danielson

	[Signature]	 	[Signature]
	Name:	 	 Bradley A. Danielson
	 	Name:	 	 Jone L. Danielson

							
	Title:	 	  
	 	Title:	 	  

	
	
	 Kevin A. Doyle, Pershing LLC Custodian

	[Print Name of Purchaser]
	
	 /s/ IRA FBO Kevin A. Doyle

	[Signature]

			
	Name:	 	 IRA FBO Kevin A. Doyle

			
	Title:	 	  

	
	
	 Zialiddin Esmail

	[Print Name of Purchaser]
	
	 /s/ Zialiddin Esmail

	[Signature]

			
	Name:	 	 Zialiddin Esmail

			
	Title:	 	  

	
	
	 SM Autogenomics LLC

	[Print Name of Purchaser]
	
	 /s/ Robert S. Feidelson

	[Signature]

			
	Name:	 	 Robert S. Feidelson

			
	Title:	 	 Member

	
	
	 Valutech Investors

	[Print Name of Purchaser]
	
	 /s/ Dennis A. Repp

	[Signature]

			
	Name:	 	 Dennis A. Repp

			
	Title:	 	 General Partner

	
	
	 AR Properties

	[Print Name of Purchaser]
	
	 /s/ Randall J. Repp

	[Signature]

			
	Name:	 	 Randall J. Repp

			
	Title:	 	 General Partner

	
	
	 Narlinger Family Partnership, LP

	[Print Name of Purchaser]
	
	 /s/ Dennis Narlinger

	[Signature]

			
	Name:	 	 Dennis Narlinger

			
	Title:	 	 Trustee

	
	
	 Jeffrey Narlinger Trust

	[Print Name of Purchaser]
	
	 /s/ Jeffrey Narlinger

	[Signature]

			
	Name:	 	 Jeffrey Narlinger

			
	Title:	 	 Trustee

	
	
	 Michael Narlinger Trust

	[Print Name of Purchaser]
	
	 /s/ Michael Narlinger

	[Signature]

			
	Name:	 	 Michael Narlinger

			
	Title:	 	 Trustee

	
	
	 Jeffrey L. Irwin IRA

	[Print Name of Purchaser]
	
	 /s/ Jeffrey L. Irwin

	[Signature]

			
	Name:	 	 Jeffrey L. Irwin

			
	Title:	 	  

	
	
	 Gleamco

	[Print Name of Purchaser]
	
	 /s/ George R. Roberts

	[Signature]

			
	Name:	 	 George R. Roberts

			
	Title:	 	 President

	
	
	 MHIC Ventures I, LLC

	[Print Name of Purchaser]
	
	 /s/ MHIC, LLC

	[Signature]

			
	Name:	 	 MHIC, LLC

			
	Title:	 	 Managing Member

	
	
	 Whitecap AG, LLC

	[Print Name of Purchaser]
	
	 /s/ William V. Andrew

	[Signature]

			
	Name:	 	 William V. Andrew

			
	Title:	 	 Manager

							
		
	 Anchan Family Trust
	 	
	[Print Name of Purchaser]	 	
		
	 /s/ Richard J. Anchan
	 	
	[Signature]	 	
	Name:	 	 Richard J. Anchan
	 	 	 	

							
	Title:	 	  
	 	 	 	

							
			
	 Paul Hazen and Cassandra Hazen, as Co-Trustees

of The Paul and Cassandra Hazen Trust
	 		 	
	[Print Name of Purchaser]	 		 	
		
	 /s/ Paul Hazen
	 	 /s/ Cassandra Hazen

	[Signature]	 	[Signature]
	Name:	 	 Paul Hazen
	 	Name:	 	 Cassandra Hazen

							
	Title:	 	 Co-Trustee
	 	Title:	 	 Co-Trustee

							
			
	 Steve Hazen and David Duron, as Co-Trustees

of The David Duran 2005 Gift Trust
	 		 	
	[Print Name of Purchaser]	 		 	
		
	 /s/ Steve Hazen
	 	 /s/ David Duron

	[Signature]	 	[Signature]
	Name:	 	 Steve Hazen
	 	Name:	 	 David Duron

							
	Title:	 	 Co-Trustee
	 	Title:	 	 Co-Trustee

							
		
	 Steve Hazen and Brandt Hazen, as Co-Trustees

of The Brandt Hazen 2005 Gift Trust
	 	
	[Print Name of Purchaser]	 	
		
	 /s/ Steve Hazen
	 	 /s/ Brandt Hazen

	[Signature]	 	[Signature]
	Name:	 	 Steve Hazen
	 	Name:	 	 Brandt Hazen

							
	Title:	 	 Co-Trustee
	 	Title:	 	 Co-Trustee

							
		
	 Steve Hazen and Brooke Hazen, as Co-Trustees

of The Brooke Hazen 2005 Gift Trust
	 	
	[Print Name of Purchaser]	 	
		
	 /s/ Steve Hazen
	 	 /s/ Brooke Hazen

	[Signature]	 	[Signature]
	Name:	 	 Steve Hazen
	 	Name:	 	 Brooke Hazen

							
	Title:	 	 Co-Trustee
	 	Title:	 	 Co-Trustee

							
			
	 Daniel M. Ardell and Jean M. Ardell Trust,

Dated February 23, 1994
	 		 	
	[Print Name of Purchaser]	 		 	
		
	 /s/ Daniel M. Ardell
	 	
	[Signature]	 	
	Name:	 	 Daniel M. Ardell
	 	 	 	

							
	Title:	 	 Co-Trustee
	 	 	 	

							
			
	 Ron and Helen Matthews Family Trust
	 		 	
	[Print Name of Purchaser]	 		 	
		
	 /s/ Roland G. Matthews
	 	
	[Signature]	 	
	Name:	 	 Roland G. Matthews
	 	 	 	

							
	Title:	 	  
	 	 	 	

							
		
	 Amended and Restated Robinson Family Trust

dtd 2/19/03
	 	
	[Print Name of Purchaser]	 	
		
	 /s/ James A. Robinson
	 	
	[Signature]	 	
	Name:	 	 James A. Robinson
	 	 	 	

							
	Title:	 	 Trustee
	 	 	 	

	
	
	 James A. Robinson, Jr.

	[Print Name of Purchaser]
	
	 /s/ James A. Robinson, Jr.

	[Signature]

			
	Name:	 	 James A. Robinson, Jr.

			
	Title:	 	  

	
	
	 Ernest Hwang

	[Print Name of Purchaser]
	
	 /s/ Ernest Hwang

	[Signature]

			
	Name:	 	 Ernest Hwang

			
	Title:	 	  

	
	
	 Elyse B. Repp

	[Print Name of Purchaser]
	
	 /s/ Elyse B. Repp

	[Signature]

			
	Name:	 	 Elyse B. Repp

			
	Title:	 	  

	
	
	 IAS Management, LLC

	[Print Name of Purchaser]
	
	 /s/ Dennis Narlinger

	[Signature]

			
	Name:	 	 Dennis Narlinger

			
	Title:	 	 Managing Member

  

	
	
	 Narlinger Family Partnership LP

	[Print Name of Purchaser]
	
	 /s/ Dennis Narlinger

	[Signature]

			
	Name:	 	 Dennis Narlinger

			
	Title:	 	 General Partner

	
	
	 Richard T. Wheeler

	[Print Name of Purchaser]
	
	 /s/ Richard T. Wheeler

	[Signature]

			
	Name:	 	 Richard T. Wheeler

			
	Title:	 	  

	
	
	 Robert A. Levin

	[Print Name of Purchaser]
	
	 /s/ Robert A. Levin

	[Signature]

			
	Name:	 	 Robert A. Levin

			
	Title:	 	  

	
	
	 Kevin A. Doyle

	[Print Name of Purchaser]
	
	 /s/ Kevin A. Doyle

	[Signature]

			
	Name:	 	 Kevin A. Doyle

			
	Title:	 	  

							
		
	 Camden C. Danielson
	 	
	[Print Name of Purchaser]	 	
		
	 /s/ Camden C. Danielson
	 	
	[Signature]	 	
	Name:	 	 Camden C. Danielson
	 	 	 	

							
	Title:	 	  
	 	 	 	

							
			
	 Michel LaPlante
	 		 	
	[Print Name of Purchaser]	 		 	
		
	 /s/ Michel LaPlante
	 	
	[Signature]	 	
	Name:	 	 Michel LaPlante
	 	 	 	

							
	Title:	 	  
	 	 	 	

							
			
	 The Danielson Family Trust
	 		 	
	[Print Name of Purchaser]	 		 	
		
	 /s/ Art Danielson
	 	 /s/ M.L. Danielson

	[Signature]	 	[Signature]
	Name:	 	 Art Danielson
	 	Name:	 	 M.L. Danielson

							
	Title:	 	 Trustee
	 	Title:	 	 Trustee

							
		
	 Karen L. Danielson
	 	
	[Print Name of Purchaser]	 	
		
	 /s/ Karen L. Danielson
	 	
	[Signature]	 	
	Name:	 	 Karen L. Danielson
	 	 	 	

							
	Title:	 	  
	 	 	 	

	
	
	 AHI/NTI Associates, LLC

	[Print Name of Purchaser]
	
	 /s/ Robyn C. Davis

	[Signature]

			
	Name:	 	 Robyn C. Davis

			
	Title:	 	 Manager

	
	
	 William H. Davidson

	[Print Name of Purchaser]
	
	 /s/ William H. Davidson

	[Signature]

			
	Name:	 	 William H. Davidson

			
	Title:	 	 Director

	
	
	 Charles Tobias Swinter

	[Print Name of Purchaser]
	
	 /s/ Charles Swinter

	[Signature]

			
	Name:	 	 Charles T. Swinter

			
	Title:	 	  

	
	
	 The Testman Trust

	[Print Name of Purchaser]
	
	 /s/ Thomas R. Testman

	[Signature]

			
	Name:	 	 Thomas R. Testman

			
	Title:	 	 Trustee

	
	
	 Thomas V. Hennessey, Jr.

	[Print Name of Purchaser]
	
	 /s/ Thomas V. Hennessey, Jr.

	[Signature]

			
	Name:	 	 Thomas V. Hennessey, Jr.

			
	Title:	 	  

  

	
	
	 Jay Penske

	[Print Name of Purchaser]
	
	 /s/ Jay Penske

	[Signature]

			
	Name:	 	 Jay Penske

			
	Title:License Agreement dated April 14, 2006

 EXHIBIT 10.8 
 CONFIDENTIAL 
 NON-EXCLUSIVE SUB-LICENSE AGREEMENT 

BETWEEN MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH 
 AND AUTOGENOMICS, INC. 
 This License Agreement (“Agreement”), dated
April 14, 2006, is between AutoGenomics, Inc., a Delaware corporation having an address at 2251 Rutherford Road, Carlsbad, CA 92008, (“LICENSEE”), and Mayo Foundation for Medical Education and Research, a Minnesota corporation, having
an address at 200 First Street SW, Rochester, MN 55905, (“MAYO”). Each hereunder may be referred to separately as the (“Party”), or together as the (“Parties”). The Parties agree: 

WHEREAS, MAYO licensed certain patents related to UGT1A1, as further identified below, from the University of Chicago (“University”) pursuant
to a license agreement dated November 18, 2005 (“License Agreement”), and 
 WHEREAS, MAYO has the authority and desire to grant
non-exclusive sublicenses to such patents, and 
 WHEREAS, LICENSEE desires to obtain a non-exclusive sublicense to such patents. 

NOW THEREFORE, in consideration of the mutual promises contained herein, the sufficiency of which is hereby acknowledged, the parties have agreed as
follows: 
 Section 1. Definitions 

The following capitalized terms used in this Agreement shall mean: 

 

	 	A.	“Affiliate” means, as to any person or entity, any other person or entity, which directly or indirectly controls, is controlled by or is under common control
with such person or entity. Control shall mean the right to control, or actual control of, management of such other entity, whether by ownership of voting securities, by agreement, or otherwise or by the direct or indirect ownership of the maximum
percentage of such stock permitted under local laws or regulations in those countries where fifty percent (50%) ownership by a foreign entity is not permitted. 

 

	 	B.	 “Calendar Quarter” means each of the four, three-month periods ending on
March 31st, June 30th, September 30th, and December 31st. 

 

	 	C.	“Effective Date” means the date set forth on the first line of the first page of this Agreement. 

 

	 	D.	“Field” means commercial diagnostic testing services for detection of UGT1A1 in humans. Field does not include the research, development, manufacture,
marketing, or sale of therapeutic products. Commercial diagnostic testing services shall include, but not be limited to, in-house laboratory tests pursuant to CLIA, clinical trials testing, and the manufacture, use and sale of diagnostic kits.

  
 Page 1 of 12

	 	E.	“Licensed Patents” means the patent applications listed on SCHEDULE A attached hereto, including all divisions, continuations, continuations-in part to the
extent that University owns or controls the patent rights, foreign counterparts, and any patents which may issue there from and any reissues, reexaminations, renewals, substitutions, or extensions of or to any such patents or patent applications.

  

	 	F.	“Licensed Product” means any product (including any apparatus or kit) or component part or testing service covered by the scope of any Valid Claim contained
in any Licensed Patent or a product made by a process, method or technique covered by the scope of any Valid Claim in any Licensed Patent or methods of using or manufacturing any product or testing service covered by the scope of any Valid Claim in
any Licensed Patent. 

  

	 	G.	“Net Sales” means: the amount billed, invoiced or received (whichever occurs first) from third parties for sales, leases or other transfers of Licensed
Products less the following amounts: 

  

	 	i.	customary trade, quantity or cash discounts and rebates, contractual allowance adjustments from third party payers, actually allowed and taken;

  

	 	ii.	amounts repaid or credited to customers on account of rejections or returns; and 

 

	 	iii.	to the extent separately stated on purchase orders, invoices, or other documents of sale, taxes levied on and/or other governmental charges made as to production, sale,
transportation, delivery or use and paid by or on behalf of LICENSEE; and 

  

	 	iv.	reasonable charges for delivery or transportation provided by third parties, if separately stated. 

Net Sales also includes the fair market value of any non-cash consideration received by LICENSEE for the sale of Licensed Products. Fair market value
will be calculated as of the time of transfer of such non-cash consideration to LICENSEE. The Parties shall use their commercially reasonable efforts to mutually agree to the fair market value. If the Parties do not reach a mutual agreement, the
Parties within sixty (60) days shall then submit the determination to a mutually acceptable third party. Under no circumstances shall the fair market value so determined exceed that amount that would be paid in an arm’s length transaction
based on the royalty rate set forth in Section 3B as applied to units sold of the Licensed Product. 
  

	 	H.	“Royalty(ies)” means all amounts payable under Section 3.B of this Agreement. 

 

	 	I.	“Territory” means worldwide. 

  
 Page 2 of 12

	 	J.	“Valid Claim” means an issued claim of any unexpired patent which has not been held unenforceable, unpatentable or invalid by a decision of a court or
governmental body of competent jurisdiction, in a ruling that is unappealable or unappealed within the time allowed for appeal; which has not been rendered unenforceable through disclaimer or otherwise; and which has not been lost through an
interference proceeding. 

 Section 2. Grant 

 

	 	A.	Grant. Subject to the terms and conditions of this Agreement, MAYO hereby grants LICENSEE a non-exclusive sublicense, without the right to sublicense others,
under the Licensed Patents to make, have made, use, import, have sold, offer to sell and sell Licensed Products within the Field and within the Territory. 

  

	 	B.	U.S. Laws. The inventions claimed in the Licensed Patents were developed with the use of United States government funds. Therefore, any right granted in this
Agreement greater than that permitted under Public Law 96-517 (The Bayh-Dole Act of 1980) or Public Law 98-620 (The Trademark Clarification Act of 1984) shall be subject to modification as may be required to conform to the provisions of those laws.
To the best of its knowledge and belief, MAYO represents that as of the Effective Date no modification of any right granted is required to conform with such laws. 

 

	 	C.	No Other Rights. No rights in and to the Licensed Patents other than those provided in this Section 2, express or implied, are conveyed by MAYO or
University. No rights to any patents except those included in Licensed Patents are conveyed by University or MAYO. 

 Section 3. Payments 
  

	 	A.	Upfront Payment. LICENSEE shall pay MAYO the sum of seventy five thousand dollars (US$75,000), which shall not be creditable against Royalties. Payments shall be
made within thirty-five (35) days of the Effective Date. 

  

	 	B.	Royalties. LICENSEE shall pay MAYO a Royalty equal to six percent (6%) of Net Sales of Licensed Products by LICENSEE or its Affiliates, which Royalty may be
creditable only as set forth below in Section 3D. 

  

	 	C.	FDA Approval. Upon application to the United States Food and Drug Administration for the commercial sale of an in vitro diagnostic kit developed by LICENSEE that
incorporates a Licensed Product as defined in Section 1.F.above, LICENSEE shall pay MAYO a one-time “Application Fee” of $25,000 within thirty (30) days of such FDA application by LICENSEE. Upon approval from the United States Food
and Drug Administration for the commercial sale of an in vitro diagnostic kit developed by LICENSEE that incorporates a Licensed Product as defined in Section l.F.above, LICENSEE shall pay MAYO a one-time “Approval Fee” of $25,000 within
thirty (30) days of such FDA approval. 

  
 Page 3 of 12

	 	D.	“Combination Service” means a Licensed Product offered as part of a package in combination with another product or service (e.g. a screening panel of
diagnostic tests) or together with a non-testing service(s) such as a specialized interpretive service or a consultative service (e.g. genetic counseling), where the Licensed Product is not separately billed. 

Reduction for Combination Services. For each Combination Service that SUBLICENSEE intends to offer pursuant to this Agreement:

  

	 	i.	SUBLICENSEE shall notify MAYO of such proposed Combination Service, such notice to include a complete description of the proposed Combination Service; and

  

	 	ii.	SUBLICENSEE may propose A commercially reasonable fraction or percentage of the fees associated with the Combination Service, that relate to the Licensed Product, that
would be used for calculation of the respective Net Sales for the calculation of the royalty due hereunder, and 

  

	 	iii.	MAYO must respond within sixty (60) days that MAYO will negotiate in good faith with SUBLICENSEE to identify a reasonable allocation of Net Sales for the
Combination Service. Otherwise, the fraction or percentage proposed by SUBLICENSEE shall be deemed accepted. 

Notwithstanding anything to the contrary, the fraction or percentage of the Net Sales for the Combination Service allocated to the
Licensed Product shall not be lower than fifteen percent (15%) of the Net Sales. 
  

	 	E.	Payment and Reporting of Royalties. Time is of the essence with respect to all payments made by LICENSEE to MAYO. All payments shall be made in U.S. currency
within forty-five (45) days after the end of each Calendar Quarter during the term of this Agreement, beginning with the Calendar Quarter in which the first commercial sale of a Licensed Product occurs. Any necessary conversion of currency into
United States dollars shall be at the applicable rate of exchange of Citibank, N.A., in New York, New York, on the last day of the Calendar Quarter in which such transaction occurred. Payments should be mailed to the following address:

 Mayo Foundation for Medical Education and Research 

3050 Superior Drive NW 
 Rochester, MN 55901 
 Attn: Todd Lechtenberg 

 

	 	F.	Royalty Reports. Each payment shall be accompanied by a statement, verified and signed by a designated representative or officer of LICENSEE and certified as
accurate, showing Net Sales for each country in the Territory and calculation of the Royalties due. 

  
 Page 4 of 12

	 	G.	Overdue Payments. Payments due to MAYO under this Agreement shall, if not paid when due under the terms of this Agreement, bear simple interest at the lower of
the prime rate of interest (as published by Citibank, N.A. on the date such payment is due) plus one and one-half percent (1.5%) or the highest rate permitted by law, calculated on the basis of a 360-day year for the number of days actually
elapsed, beginning on the due date and ending on the day prior to the day on which payment is made in full. LICENSEE shall pay for all costs and fees including reasonable attorney’s fees that MAYO must expend in order to collect any amounts due
and owing to MAYO after reasonable attempts have been made to collect the amounts or, in MAYO’S discretion, after the amounts remain outstanding for a period of ninety (90) days from the payment due date. 

Section 4. Records and Reporting 
  

	 	A.	Full and Accurate Records. MAYO may from time to time and at any reasonable time, not exceeding once every twelve (12) months, by a professional accountant
selected by MAYO and acceptable to LICENSEE, such acceptance not to be unreasonable withheld, inspect the books and records of LICENSEE and its Affiliates in order to verify the accuracy of reported statement by LICENSEE of sums paid or payable, or
of any other material obligation under this Agreement. The MAYO representative shall treat as confidential all materials and information obtained as a result of such inspection. LICENSEE shall, and shall cause its Affiliates to keep full and
accurate books and records in sufficient detail so that LICENSEE’s obligations under this Agreement can be properly determined. Such books and records shall be maintained for at least five (5) years after the Royalty reporting
period (s) to which they relate. After completion of any such examination, MAYO shall promptly notify LICENSEE in writing of any proposed modification to LICENSEE’s statement of sums due and payable. Such examination shall be made at the
expense of MAYO, unless such examination reasonably demonstrates the amount of Royalties and other payments due MAYO have been underpaid by 5% or more. In such case LICENSEE shall be responsible for reimbursing MAYO for the reasonable examination
fee and expenses charged by the auditor. 

 Section 5. Patents 

 

	 	A.	Prosecution and Maintenance MAYO will coordinate with University in the prosecution, maintenance and enforcement of the Licensed Patents. MAYO shall use
commercially reasonable efforts to duly and punctually perform any necessary obligation related to prosecution, maintenance, and enforcement provisions under the License Agreement. 

 

	 	B.	Infringement. LICENSEE may inform MAYO if it becomes aware that a third party is infringing the Licensed Patents. 

  
 Page 5 of 12

 Section 6. Term and Termination 

 

	 	A.	Term. Unless terminated earlier, this Agreement shall expire on the expiration date of the last to expire of the Licensed Patents. This Agreement shall
immediately terminate upon termination of the License Agreement for any reason. MAYO will promptly notify LICENSEE of any such termination of the License Agreement. 

 

	 	B.	MAYO’S Right to Terminate. MAYO shall have the right to terminate this Agreement as follows, in addition to all other available remedies:

  

	 	i.	If LICENSEE fails to make any Royalty or other payment when due, this Agreement shall terminate effective thirty (30) days after MAYO’S written notice to
LICENSEE to such effect, unless LICENSEE makes such payment within the thirty (30) days. 

  

	 	ii.	If LICENSEE fails to observe any other material obligation of this Agreement, this Agreement shall terminate effective thirty (30) days after MAYO’S written
notice to LICENSEE describing such failure, unless LICENSEE cures such failure within the thirty (30) days. 

  

	 	iii.	If LICENSEE shall have filed by or against it a petition under any bankruptcy or insolvency law it shall immediately notify MAYO. If such petition is not dismissed
within sixty (60) days of its filing, or if LICENSEE makes an assignment of all or substantially all of its assets for the benefit of its creditors LICENSEE shall immediately notify MAYO and MAYO may terminate this Agreement by written notice
effective as of the (i) date of filing by LICENSEE of any such petition, (ii) date of any such assignment to creditors, or (iii) end of the sixty (60) days if a petition is filed against it and not dismissed by such time,
whichever is applicable. 

  

	 	iv.	If LICENSEE shall be dissolved, liquidated or otherwise ceases to exist, other than a because of a corporate reorganization of LICENSEE and its Affiliates, this
Agreement shall automatically terminate as of (i) the date articles of dissolution or a similar document is filed on behalf of LICENSEE with the appropriate government authority or (ii) the date of establishment of a liquidating trust or
other arrangement for the winding up of the affairs of LICENSEE. 

  

	 	C.	LICENSEE’S Right to Terminate. LICENSEE may terminate this Agreement at any time by giving MAYO ninety (90) days prior written notice.

  

	 	D.	Survival. All causes of action accruing to either party under this Agreement shall survive termination for any reason, as well as (i) LICENSEE’s
obligation to pay Royalties on Net Sales that arose from Licensed Product transactions that occurred during the term of the Agreement under Section 3; and (ii) LICENSEE’S obligation to report Net Sales that arose from Licensed Product
transactions that occurred during the term of the Agreement and record keeping required by Section 4. Sections 6D, 6E, 7,8I, shall survive termination or expiration of this Agreement for any reason. 

  
 Page 6 of 12

	 	E.	Post Termination, Post Expiration Obligations of LICENSEE. Upon the termination of this Agreement for any reason, or the expiration of this Agreement, all rights
of LICENSEE to use the Licensed Patent(s) provided to LICENSEE under this Agreement, shall immediately thereafter cease. Upon such termination or expiration, all tangible materials, including all copies shall be transferred to MAYO or, at
MAYO’S discretion, destroyed in part or in whole by LICENSEE and LICENSEE shall provide to the MAYO a certification that such partial or complete destruction has been completed. LICENSEE shall not thereafter operate or conduct business under
any name or mark and in any manner in the Territory that might tend to give the market the impression that this Agreement is still in force, or that LICENSEE has any right to use any Licensed Patent(s), any trademark or service mark of MAYO OR
University, and/or any tangible property owned by University or MAYO in the Territory. All payments including fees and costs due under this Agreement and not paid yet shall become due and payable within thirty (30) days after termination. Upon
expiration or termination, LICENSEE shall cease using University’s or MAYO’s name or any of the University’s or MAYO’S trade names under which the LICENSEE has offered Licensed Products. 

Section 7. Warranties; Indemnification; Insurance 

 

	 	A.	Warranties. MAYO represents and warrants to LICENSEE that it may grant the sublicense set forth herein under the License Agreement with University. MAYO further
represents and warrants to LICENSEE that should the License Agreement with University terminate for any reason, except expiration of the License Agreement, that the License Agreement with University provides that University will directly sublicense
LICENSEE under similar terms and conditions set forth in this Agreement provided that LICENSEE is not in default of its obligations to MAYO. 

  

	 	B.	Disclaimer of Warranties. Except as otherwise stated in this Agreement, MAYO and University make no representations or warranties of any kind, express or
implied, with respect to the invention(s) claimed in the Licensed Patents or with respect to the Licensed Patents themselves, including but not limited to, any representations or warranties about (i) the validity, scope or enforceability of any
of the Licensed Patents; (ii) the accuracy, safety or usefulness for any purpose of any information provided by University or MAYO with respect to the invention(s) claimed in the Licensed Patents or with respect to the Licensed Patents
themselves and any products developed from or covered by them; (iii) whether the practice of any claim contained in any of the Licensed Patents will or might infringe a patent or other intellectual property right owned or licensed by a third
party; (iv) the patentability of any invention claimed in the Licensed Patents; or (v) the accuracy, safety, or usefulness for any purpose of any product or process made or carried out in accordance with or through the use of the Licensed
Patents. 

  

	 	C.	 Indemnification. LICENSEE agrees, and agrees to cause its Affiliates to defend and hold harmless University and MAYO, and their respective
Affiliates and all trustees, directors, officers, employees, fellows and agents of any of the foregoing (each an “Indemnified Person”) from and against any and all third party claims, demands, loss, damage, penalty, cost or expense
(including attorneys’ and witnesses’ fees and costs) of any kind or nature, based upon, or arising out of any cause of action arising from 

  
 Page 7 of 12

 
the development, production, use, sale or other disposition of Licensed Products and all activities associated therewith by LICENSEE and its Affiliates, or any use of information provided by
University or MAYO to LICENSEE provided however, such indemnity shall not extend to damages arising from any breach of the Agreement or willful or negligent act by MAYO and provided that: (i) MAYO promptly notifies LICENSEE of the claim in
writing;; and ii) MAYO provides LICENSEE with the assistance, information and authority necessary to perform LICENSEE’S obligations under this Section. LICENSEE agrees and agrees to cause each of its Affiliates to agree not to sue University
and its Affiliates and all trustees, directors, officers, employees, fellows and agents of University in connection with the development, production, use, sale or other disposition of Licensed Products and all activities associated therewith.
University and MAYO shall be entitled to participate at its option and expense through counsel of its own selection, and may join in any legal actions related to any such claims, demands, losses, damages, costs, expenses and penalties. LICENSEE
shall not enter into any settlement which includes an admission of negligence or wrongdoing by any Indemnified Person, without the prior written consent of such party. 
  

	 	D.	Assumption of Risk. Neither University nor any party to this Agreement, nor any of such parties’ respective trustee, directors, officers, employees, fellows
or agents shall be responsible or liable for any injury, loss, or damage of any kind, including but not limited to indirect, special, incidental consequential, punitive damages or lost profits. The above limitations on liability apply even though a
party may have been advised of the possibility of such injury, loss or damage. This Section shall not apply to LICENSEE’S obligation to indemnify in this Agreement. 

 

	 	E.	Insurance. LICENSEE agrees and agrees to cause its Affiliates to maintain liability insurance that shall cover any claims for bodily injury, property, or other
damage alleged to relate to Licensed Products. LICENSEE and Affiliates shall list University, MAYO, and their Affiliates, at LICENSEE’S or Affiliates’ expense, whichever is relevant, as additional insured under its general commercial
liability insurance policy that LICENSEE and its Affiliates have or shall obtain, that includes any coverage of claims relating to Licensed Products. Such insurance shall be primary and noncontributory to any insurance University or MAYO may have.
At MAYO’S request, LICENSEE will supply MAYO with evidence of such coverage, and will notify MAYO in writing at least thirty (30) days prior to any termination of or material change in coverage under any such policies.

 Section 8. Miscellaneous 

 

	 	A.	Marking. If commercially feasible, LICENSEE shall and agrees to cause its Affiliates, to place in a conspicuous location on Licensed Products (or its packaging
where marking the Licensed Product is physically impossible) sold to third parties, a patent notice in accordance with the laws concerning the marking of patented articles in the country in which such articles are sold. 

 

	 	B.	US Manufacture. LICENSEE agrees that any Licensed Products will be manufactured substantially in the United States of America as required by 35 United States
Code Section 204. 

  
 Page 8 of 12

	 	C.	Export Regulations. To the extent that the United States Export Control Regulations are applicable, neither LICENSEE nor University shall, without having first
fully complied with such regulations, (i) knowingly transfer, directly or indirectly, any unpublished technical data obtained or to be obtained from the other party hereto to a destination outside the United States, or (ii) knowingly ship,
directly or indirectly, any product produced using such unpublished technical data to any destination outside the United States. 

  

	 	D.	Entire Agreement, Amendment, Waiver. This Agreement together with the Schedules attached hereto constitutes the entire agreement between the parties regarding
the subject matter hereof, and supersedes all prior written or oral agreements or understandings (express or implied) between them concerning the same subject matter. This Agreement may not be amended or modified except in a document signed by duly
authorized representatives of each party. No waiver of any default hereunder by either party or any failure to enforce any rights hereunder shall be deemed to constitute a waiver of any subsequent default with respect to the same or any other
provision hereof. Notwithstanding anything to the contrary in this Agreement, the confidentiality agreement entered into between the parties and effective December 5,2005, shall remain in full force and effect. 

 

	 	E.	Notice. Any notice required or otherwise made pursuant to this Agreement shall be in writing, sent by registered or certified mail properly addressed, or by
facsimile with confirmed answer-back, to the other party at the address set forth below or at such other address as may be designated by written notice to the other party. Notice shall be deemed effective three (3) business days following the
date of sending such notice if by mail, on the day following deposit with an overnight courier, if sent by overnight courier, or upon confirmed answer-back if by facsimile. 

 

	 	    	If to LICENSEE: AutoGenomics Inc 

			
	 	  	 2251 Rutherford Road

Carlsbad, CA 92008
 Attn: Fareed
Kureshy
 Facsimile Number: 760-804-7382

  

	 	    	If to MAYO: MAYO Foundation for Medical Education and Research 

			
	 	  	 3050 Superior Drive SW

Rochester, MN 55901
 Attn: David
Herbert
 Facsimile Number: 507-538-1278

  

	 	    	With copy to: MAYO Foundation for Medical Education and Research 

			
	 	  	 200 First Street SW

Rochester, MN 55905

 Attn: Legal Department 

  
 Page 9 of 12

	 	F.	Assignment. LICENSEE may not assign or delegate this Agreement or any of its obligations hereunder without the prior written consent of MAYO, which shall not be
unreasonably withheld. This Agreement shall be binding on the parties hereto and upon their permitted successors and assigns. 

  

	 	G.	Change of Control. To the extent permitted by applicable law, in the event of a Change in Control, as defined in this Section, LICENSEE shall notify MAYO at
least thirty (30) days before the effective date of such Change in Control. A “Change of Control” shall mean the occurrence of one of the following events during the term of this Agreement: (i) any transaction in which the
LICENSEE is to be consolidated with or acquired by another entity in a merger, tender offer or other reorganization in which the holders of the outstanding voting stock of the LICENSEE immediately preceding the consummation of such event, shall,
immediately following such event, hold, as a group, less than a majority of the voting securities of the surviving or successor entity, or (ii) the sale of all or substantially all of the LICENSEE’S assets. 

 

	 	H.	Governing Law. The interpretation and performance of this Agreement shall be governed by the laws of the State of Minnesota, without consideration of conflicts
of laws provisions. 

  

	 	I.	No Use of Name. Neither Party shall use the name of the other Party in any commercial activity, marketing, advertising or sales brochures except with the prior
written consent of the other Party, which consent may be granted or withheld at such Party’s sole discretion. The Parties agree not to use the name of either Party’s employee(s) in any commercial activity, marketing, advertising or sales
brochures. 

  

	 	J.	Force Maieure. No failure or omission by either party in the performance of any obligation of this Agreement shall be deemed a breach of this Agreement or create
any liability if the same shall arise from any cause or causes beyond the control of the parties, including, but not limited to, the following, which, for the purposes of this Agreement, shall be regarded as beyond the control of the party in
question: Act of God; act or omission of any government; any rule, regulation or order issued by any governmental authority or by any officer, department, agency, or instrumentality thereof; fire; storm; flood; earthquake; accident; war; rebellion;
insurrection; riot; invasion; strike; and lockout. 

  

	 	K.	Construction. This Agreement shall be construed without regard to the Party or Parties responsible for the preparation of the same and shall be deemed as
prepared jointly by the Parties. Any ambiguity or uncertainty existing herein shall not be interpreted or construed against any Party. 

  

	 	L.	Execution. This Agreement may be executed by the Parties in any number of identical counterparts, each of which, for all purposes shall be deemed to be an
original, and all of which shall constitute, collectively, one instrument. 

  
 Page 10 of 12

	 	M.	Severability. If any provision of this Agreement shall be held illegal, unenforceable, or in conflict with any laws of any federal, provincial, state, or local
government that may jurisdiction over this Agreement, the validity of the remaining portions or provisions shall not be affected thereby. 

 IN WITNESS WHEREOF, the parties hereto have caused this agreement to be executed by their respective duly authorized officers or representatives on the date first above written. 

 

									
	AutoGenomics, Inc.	 		 	Mayo Foundation for Medical Education and Research
					
	By:	 	/s/ Fareed. Kureshy	 		 	By:	 	/s/ Jonathan J. Oviett
		 	Fareed. Kureshy	 		 		 	Jonathan J. Oviett
		 	President & CEO	 		 		 	Secretary
		 	Date of Signature: April 14th 2006	 		 		 	Date of Signature: 4.19.06

  
 Page 11 of 12

 SCHEDULE A 
  

											
	 UCHI
	  	Domain	  	Status	  	Pat App No	  	Filing Date	  	Patent No
	 UCHI 0516
	  	US	  	Issued	  	08/423,641	  	04/17/95	  	5,786,344
	 UCHI 0516
	  	Canada	  	Pending	  	2,194,277	  	07/05/95	  	
	 UCHI 0516
	  	EPO	  	Issued	  	95 925 476.4	  	07/05/95	  	
	 UCHI 0S16
	  	UK	  	Issued	  	95 925 476.4	  	07/05/95	  	
	 UCHI 0516
	  	Ireland	  	Issued	  	95 925 476.4	  	07/05/95	  	
	 UCHI 0516
	  	Luxembourg	  	Issued	  	95 925 476.4	  	07/05/95	  	
	 UCHI 0516
	  	Japan	  	Pending	  	8-503964	  	07/05/95	  	
	 UCHI 0693
	  	US	  	Issued	  	09/251,274	  	02/16/99	  	6,395,481
	 UCHI 0693
	  	US	  	Issued	  	10/061,693	  	02/01/02	  	6,472,157
	 UCHI 0693
	  	US	  	Pending	  	10/277,160	  	10/21/02	  	
	 UCHI 1014
	  	US	  	Pending	  	10/751,606	  	01/05/04	  	
	 UCHI 1116
	  	PCT	  	Pending	  	PCT/US04/16920	  	05/28/04	  	

  
 Page 12 of 12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00208-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00208-of-00352.parquet"}]]